Hepatitis B Journal Articles

• Incidence and Mortality of HBV and HCV, Cirrhosis and HCC This article provides an update on the global incidence and mortality rates for these liver diseases. How have they changed in recent years?
  Journal of Viral Hepatitis, May 23, 2022
• Comorbidities and Co-Medications Among People With HIV How prevalent are comorbidities and the use of non-ART co-medications among people living with HIV?
  HIV Medicine, May 19, 2022
• Overt HE in Cirrhotic Patients With Acute Decompensation This study aimed to determine whether the occurrence of overt hepatic encephalopathy is an independent risk factor for de novo infection in patients with cirrhosis and acute decompensation.
  Alimentary Pharmacology & Therapeutics, April 27, 2022
• Integrating HCV Screening of Baby Boomers at a Hospital ED This paper details the implementation of an opt-in HCV screening program for baby boomers presenting to a community hospital emergency department.
  Journal of Viral Hepatitis, April 18, 2022
• Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety Do tenofovir and entecavir differ in their long-term impact on renal function in patients with hepatitis B?
  Journal of Viral Hepatitis, April 11, 2022
• Chronic Hepatitis D--What Is Changing? Several new approaches to hepatitis D virus therapy have been explored in recent years. Review these advances and novel therapeutic options for HDV in this paper.
  Journal of Viral Hepatitis, April 04, 2022
• Hepatitis D Hospitalizations in the U.S.: 2010-2018 A new study provides insight into the hospitalization rates of hepatitis D in the U.S. and the various characteristics of these patients.
  Journal of Viral Hepatitis, March 31, 2022
• Overseas Treatment of Latent TB in US-Bound Immigrants Could TB testing and treatment of immigrants before arrival in the U.S. help prevent the importation of the disease?
  Emerging Infectious Diseases, March 22, 2022
• The Impact of Waves of COVID-19 on HBV and HCV Testing In what ways were HBV and HCV testing impacted during the first three waves of the COVID-19 pandemic? A new study examines the trends.
  Journal of Viral Hepatitis, March 17, 2022
• Epidemiological and Clinical Features of MAFLD and NAFLD The transition from the nomenclature NAFLD to MAFLD remains heavily debated. How do their epidemiological and clinical features compare, and is MAFLD the preferable terminology?
  Liver International, March 14, 2022
• Hepatocellular Carcinoma in Noncirrhotic and Cirrhotic livers What are the clinicopathologic differences between hepatocellular carcinoma arising in noncirrhotic and cirrhotic livers?
  American Journal of Clinical Pathology, March 09, 2022
• Role of Gut Microbiota in HBV Disease Progression and Treatment This review aims to clarify our understanding of the pathophysiology of gut microbiota and their relationship with liver injury in chronic hepatitis B. How might this inform future therapeutics?
  Journal of Viral Hepatitis, February 21, 2022
• Risk of HCC in Chronic Viral Hepatitis With Fatty Liver How does fatty liver impact the risk of hepatocellular carcinoma and mortality in patients with chronic viral hepatitis?
  Alimentary Pharmacology & Therapeutics, February 01, 2022
• Long-term Changes of Liver Stiffness in DAA Anti-HCV Therapy How does SVR impact the degree of fibrosis in the long-term after direct-acting antiviral HCV therapy? This study compared early vs. the long-term changes in liver stiffness that occur after therapy.
  Journal of Viral Hepatitis, January 31, 2022
• Underrecognition of NAFLD in Poorly Controlled Diabetes Poorly controlled type 2 diabetes is associated with a greater risk for NAFLD and its complications, but it remains poorly recognized in practice.
  Journal of the Endocrine Society, January 12, 2022
• COVID-19 and the Liver: Lessons Learnt a Year Later This study summarizes what we have learned concerning liver manifestations and prevalence of hepatic abnormalities in COVID-19 patients from both Eastern and Western countries.
  Journal of Viral Hepatitis, January 10, 2022
• Surface-Aerosol Stability and Pathogenicity of MERS-CoV What have we learned about the environmental stability and pathogenicity of different MERS-CoV isolates? How do they differ from SARS-CoV-2 strains?
  Emerging Infectious Diseases, January 06, 2022
• Viral and Bacterial Factors of Mother-to-Child HBV Transmission Mother-to-child transmission of HBV during delivery remains a common route of infection in developing countries. What role do viral and bacterial factors play in such cases?
  Journal of Viral Hepatitis, January 03, 2022
• Prediction Model for HCC Occurrence in Patients With HCV The authors present a validated prediction model for hepatocellular carcinoma occurrence after DAA-mediated SVR in patients with hepatitis C.
  Alimentary Pharmacology & Therapeutics, December 28, 2021
• DAAs for HCV-related HCC Patients With Multiple Recurrences Does treatment with direct-acting antivirals have a beneficial effect on HCV-related hepatocellular carcinoma patients who have had multiple courses of recurrence?
  Journal of Viral Hepatitis, December 13, 2021